Beau Webber, PhD

Co-Director, Genome Engineering Shared Resource

United States

Contact Dr. Webber:

Dr. Beau Webber is an Assistant Professor in the Department of Pediatrics, Division of Hematology and Oncology at the University of Minnesota. He graduated from the University of Wisconsin- LaCrosse in 2007 with a BS in Cellular and Molecular Biology and conducted his PhD studies at the University of Minnesota where he studied the embryonic development of hematopoietic stem cells. As a postdoctoral fellow in the Hematology, Oncology, and Transplantation program at the University of Minnesota, Dr. Webber developed advanced strategies for genetic modification of human lymphohematopoietic and pluripotent stem cells for cancer immunotherapy and correction of inherited diseases. Dr. Webber joined the Department of Pediatrics Faculty as an Assistant Professor in 2017.


PhD in Molecular, Cellular, Developmental Biology, and Genetics, University of Minnesota Medical School, Minneapolis, MN

Awards & Recognitions

  • Young Investigator Award, Alex's Lemonade Stand Foundation on behalf of Northwestern Mutual Foundation
  • Innovator, Basic Science, Department of Pediatrics, University of Minnesota (2023)
  • Children’s Cancer Research Fund (CCRF) Emerging Scientist Award
  • Basic Science Paper of the Year (Assistant Professor), Department of Pediatrics, University of Minnesota
  • Innovator in Translational Research Award, Department of Pediatrics, University of Minnesota
  • 26th Scott Murphy Memorial Lecturer, The Biomedical Excellence for Safer Transfusion Collaborative
  • University of Minnesota Sarcoma Research Award from Rein In Sarcoma

Expand all


Research Summary/Interests

Dr. Webber's laboratory is focused on synergizing genome engineering, stem cell biology, and adoptive cellular therapy to develop novel treatments for genetic disease and cancer. Research projects in the lab currently fall into two broad areas: the application of genome engineering to develop improved cell-based immune and gene therapies, and the development of "bottom-up" cancer models using human pluripotent stem cells.